Antiandrogen Monotherapy Market, by Type (Steroidal (Cyproterone Acetate), and Nonsteroidal (Bicalutamide and Flutamide)), by Disease Indication (Prostate Cancer, Benign Prostatic Hyperplasia, Hirsutism, Hyperandrogenism, and Others), by Distribution Chan
Antiandrogens are a class of drugs that prevent androgens such as testosterone and dihydrotestosterone (DHT) from mediating their biological effects in the body. Antiandrogens are used to treat men with prostate cancer, benign prostatic hyperplasia, pattern hair loss, hypersexuality, paraphilias, and priapism. In women and girls, antiandrogens are used to treat acne, seborrhea, hirsutism, and hyperandrogenism.
Antiandrogen monotherapy is an alternative treatment option to androgen-deprivation therapy (ADT) with surgical or pharmacological castration for metastatic prostate cancer. Surgical or pharmacological castration for metastatic prostate cancer are associated with loss of libido and impotence, and may not always be acceptable to the patient. Hence, antiandrogen monotherapy provides an alternative to castration in prostate cancer treatment, which is likely to boost growth of the antiandrogen monotherapy market over the forecast period.
Global Antiandrogen Monotherapy Market – Dynamics
The increasing approvals of new antiandrogen monotherapy drugs by regulatory authorities is expected to drive the market growth over the forecast period. For instance, in December 2019, Pfizer Inc. and Astellas Pharma Inc. received approval for a supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for XTANDI (enzalutamide), indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Moreover, increasing prevalence of prostate cancer is likely to propel growth of the antiandrogen monotherapy market over the forecast period. According to the World Cancer Research Fund, prostate cancer is the second most common cancer diagnosed in males and fourth most common cancer occurring overall. The World Cancer Research Fund also estimated that around 1.3 million males were diagnosed with prostate cancer globally in 2018. Such high prevalence of prostate cancer is expected to increase demand for antiandrogen monotherapy in order to treat the disease.
Global Antiandrogen Monotherapy Market - Regional Insights
On the basis of region, the antiandrogen monotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the American Society of Clinical Oncology (ASCO), around 191,930 new cases of prostate cancer is estimated to be diagnosed in the U.S., in 2020. North America holds a dominant position in the global antiandrogen monotherapy market due to increasing prevalence of prostate cancer in the region.
Europe is also showcasing high growth in antiandrogen monotherapy market due to increasing prevalence of prostate cancer. According to the Cancer Research UK, around 48,487 cases of prostate cancer were reported in the U.K. during 2015-2017.
https://www.coherentmarketinsights.com/insight/request-sample/3810
https://www.coherentmarketinsights.com/insight/request-pdf/3810
Global Antiandrogen Monotherapy Market - Competitive Landscape
Key players operating in the global antiandrogen monotherapy market include Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, OSI Pharmaceuticals, Inc., Genentech Inc., Bristol-Myers Squibb Company, Novartis AG, Progenics Pharmaceuticals, Inc., ALZA Corporation, Sanofi SA, GlaxoSmithKline Plc, Amgen Inc, ANI Pharmaceuticals, Inc., and others.
Global Antiandrogen Monotherapy Market - Market Taxonomy
On the basis of type, the global antiandrogen monotherapy market is segmented into:
· Steroidal
o Cyproterone Acetate
· Nonsteroidal
o Bicalutamide
o Flutamide
On the basis of disease indication, the global antiandrogen monotherapy market is segmented into:
· Prostate Cancer
· Benign Prostatic Hyperplasia
· Hirsutism
· Hyperandrogenism
· Others
On the basis of distribution channel, the global antiandrogen monotherapy market is segmented into:
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
On the basis of region, the global antiandrogen monotherapy market is segmented into:
· North America
· Latin America
· Europe
· Asia Pacific
· Middle East
· Africa
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
· Customized Market Research Services
· Industry Analysis Services
· Business Consulting Services
· Market Intelligence Services
· Long term Engagement Model
· Country Specific Analysis
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email: [email protected]
Source:
https://www.coherentmarketinsights.com/ongoing-insight/antiandrogen-monotherapy-market-3810